Skip to main content
. Author manuscript; available in PMC: 2018 Feb 1.
Published in final edited form as: Expert Rev Clin Pharmacol. 2017 Oct 12;11(2):151–164. doi: 10.1080/17512433.2017.1353909

Figure 1. Metabolic profiles of three major P2Y12 receptor inhibitors.

Figure 1

Compounds with P2Y12-receptor inhibiting properties are in red.

CES, human carboxylesterase; CYP, cytochrome P450; P-GP, P-glycoprotein. Reproduced with permission from British Journal of Clinical Pharmacology (2014) [16]